Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • ESMO Interview | Dr. Bryan Li: From Bladder Removal to Bladder Preservation, Perioperative Immunotherapy Reshapes MIBC Treatment

    Oncology Frontier- UroStream: From ASCO to ESMO, we’ve seen a surge of exciting new data in bladder cancer. The NIAGARA regimen is drawing great attention in the MIBC field. How…

    2025.10.22
  • CSCO 2025 | Professor Wei Li: PARP Inhibitors Transform Early BRCA-Mutated Breast Cancer — Precision and Combination Strategies Drive Progress

    Editor’s Note: Patients carrying BRCA gene mutations face a significantly increased risk of developing breast cancer, and conventional therapies often yield suboptimal results. PARP inhibitors, by leveraging the mechanism of…

    2025.10.21
  • CSCO 2025 | Professor Guohong Song: Immunotherapy Redefines Triple-Negative Breast Cancer Through Precision and Intensified Treatment

    Editor’s Note: In recent years, immunotherapy, particularly PD-1/PD-L1 inhibitors, has profoundly transformed the treatment paradigm for triple-negative breast cancer (TNBC). The KEYNOTE-522 trial demonstrated that neoadjuvant immunotherapy combined with chemotherapy…

    2025.10.21
  • The 11th Qingdao Breast Disease Conference | Professor Jian Yin: Optimizing the Management of Complications in Implant-Based Breast Reconstruction

    The 11th Qingdao Breast Disease Conference and the 9th “Langya Forum” were recently held in the beautiful coastal city of Qingdao. The event brought together leading experts and emerging talents in breast oncology from across China and beyond to share cutting-edge research, discuss innovative diagnostic and therapeutic strategies, and chart the future of breast disease…

    2025.10.21
  • Oriental Insight | Professor Juliang Zhang: Insights into Adjuvant Intensified Therapy for HR+/HER2- Breast Cancer

    Hormone receptor–positive, HER2-negative (HR+/HER2−) breast cancer is the most common molecular subtype of breast cancer. Although patients with this subtype generally have a favorable prognosis, its high heterogeneity means that some individuals remain at risk of disease recurrence.In recent years, adjuvant treatment strategies have been continuously refined — evolving from standard endocrine therapy to the…

    2025.10.21
  • Oriental Insight | Professors Xiaoyun Mao and Wen Xu’s Team Publishes a Comprehensive Review on Engineered Upconversion Nanoparticles for Precision Theranostics in Breast Cancer 

    Breast cancer remains the most common malignancy among women, with persistently high incidence and mortality rates. Its heterogeneity, drug resistance, and the toxicity associated with conventional therapies continue to challenge clinical management.In recent years, rare-earth-doped upconversion nanoparticles (UCNPs) have attracted growing attention in breast cancer research owing to their unique optical properties, tunable synthesis, and…

    2025.10.21
  • The 11th Qingdao Breast Disease Conference | Professor Xin Wang: Opportunities and Challenges in Omitting Local Therapy After Neoadjuvant Treatment

    Editor’s Note: With the expanding role of neoadjuvant therapy in breast cancer, pathologic complete response (pCR) has become an important indicator for evaluating treatment efficacy. Whether patients who achieve pCR…

    2025.10.21
  • EACS 2025 Kicks Off in Paris!

    2025.10.17
next»
Recent Posts
  • ESMO Interview | Dr. Bryan Li: From Bladder Removal to Bladder Preservation, Perioperative Immunotherapy Reshapes MIBC Treatment
  • CSCO 2025 | Professor Wei Li: PARP Inhibitors Transform Early BRCA-Mutated Breast Cancer — Precision and Combination Strategies Drive Progress
  • CSCO 2025 | Professor Guohong Song: Immunotherapy Redefines Triple-Negative Breast Cancer Through Precision and Intensified Treatment
  • The 11th Qingdao Breast Disease Conference | Professor Jian Yin: Optimizing the Management of Complications in Implant-Based Breast Reconstruction
  • Oriental Insight | Professor Juliang Zhang: Insights into Adjuvant Intensified Therapy for HR+/HER2- Breast Cancer
Recent Comments
    Archives
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2025 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Media Medic Publishing Company Limited(HK)
    赛美出版有限公司(香港)
    Scroll to Top